Moreover, when anti-VEGF agents were used as a monotherapy, neither bevacizumab nor ranibizumab reduced the risk of retinal detachment, mortality before discharge, corneal opacity requiring corneal transplant, or lens opacity requiring cataract removal [48]. This evidence concerns the gene VEGFA and cataract.